Last reviewed · How we verify
ECT-001-CB
At a glance
| Generic name | ECT-001-CB |
|---|---|
| Sponsor | Ciusss de L'Est de l'Île de Montréal |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (PHASE1, PHASE2)
- US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia (PHASE2)
- A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe. (PHASE1, PHASE2)
- UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia (PHASE2)
- US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ECT-001-CB CI brief — competitive landscape report
- ECT-001-CB updates RSS · CI watch RSS
- Ciusss de L'Est de l'Île de Montréal portfolio CI